Alyeska Investment Group
MDNA

Alyeska Investment Group’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Alyeska Investment Group’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-650,000
Closed -$298K – 570
2022
Q4 		$298K Hold
650,000
– – ﹤0.01% 387
2022
Q3 		$539K Buy
+650,000
New +$734K 0.01% 360

Other funds holding MDNA

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Alyeska Investment Group's MDNA Position: Q1 2023 in Review

Alyeska Investment Group sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q1 2023, closing a stake of 650,000 shares — an estimated $298K sold.

Alyeska Investment Group first reported a position in MDNA in Q3 2022 and held it in 2 quarters. The position peaked at $539K in Q3 2022. 27 funds tracked by Wall St. Rank hold MDNA as of Q1 2023.

  • Alyeska Investment Group reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q1 2023 after selling out during the quarter.
  • Alyeska Investment Group sold 650,000 Medicenna Therapeutics Corp. Common Shares shares in Q1 2023, an estimated $298K.
  • Alyeska Investment Group first reported a position in Medicenna Therapeutics Corp. Common Shares in Q3 2022 and held it in 2 quarters.
  • Alyeska Investment Group's Medicenna Therapeutics Corp. Common Shares position peaked at $539K in Q3 2022.
  • 27 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q1 2023.

Based on Alyeska Investment Group's 13F filing for Q1 2023, filed 15 May 2023.